IL13 and myeloid sarcoma: In a 6-month double-blind, placebo-controlled, randomized trial in vitamin D-insufficient patients with MS, 25 μg (1000 IU) vitamin D significantly increased serum levels of TGF-beta 1, while having no effect on TNF-α, IFN-γ, and IL-13 [31].